Literature DB >> 19625497

Use of chromogenic assay of factor X to accept or reject INR results in Warfarin treated patients.

Michael J Sanfelippo1, Wendy Zinsmaster, Doris L Scherr, Gene R Shaw.   

Abstract

A warfarin treated patient unexpectedly presented with an elevated international normalized ratio (INR). Repeat testing in two laboratories gave conflicting results. The chromogenic assay of factor X was used to determine the correct INR result. The patient had laboratory results consistent with a dysfibrinogenemia, which prevented detection of the endpoint with a photo-optical detection system. The chromogenic assay of factor X is recommended for monitoring patients on warfarin when the INR cannot be accurately determined due to interference with the fibrin endpoint in the INR.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19625497      PMCID: PMC2757431          DOI: 10.3121/cmr.2009.836

Source DB:  PubMed          Journal:  Clin Med Res        ISSN: 1539-4182


  4 in total

Review 1.  Dysfibrinogenemia and thrombosis.

Authors:  Timothy Hayes
Journal:  Arch Pathol Lab Med       Date:  2002-11       Impact factor: 5.534

2.  Fibrinogen Longmont: a dysfibrinogenemia that causes prolonged clot-based test results only when using an optical detection method.

Authors:  J B Lefkowitz; T DeBoom; A Weller; S Clarke; D Lavrinets
Journal:  Am J Hematol       Date:  2000-03       Impact factor: 10.047

3.  Falsely elevated INRs in warfarin-treated patients with the lupus anticoagulant.

Authors:  M J Sanfelippo; J Sennet; E J McMahon
Journal:  WMJ       Date:  2000-06

4.  Monitoring warfarin therapy in patients with lupus anticoagulants.

Authors:  S Moll; T L Ortel
Journal:  Ann Intern Med       Date:  1997-08-01       Impact factor: 25.391

  4 in total
  3 in total

1.  Prospective evaluation of a bivalirudin to warfarin transition nomogram.

Authors:  Benjamin Hohlfelder; Katelyn W Sylvester; Jessica Rimsans; David DeiCicchi; Jean M Connors
Journal:  J Thromb Thrombolysis       Date:  2017-05       Impact factor: 2.300

2.  Plasma from chronic liver disease subjects exhibit differential ability to generate thrombin.

Authors:  Zhineng J Yang; Siddharth H Sheth; Chad H Smith; Amy R Schmotzer; Anita L Lippello; Ali Al-Khafaji; Kapil B Chopra; Roy E Smith
Journal:  Blood Coagul Fibrinolysis       Date:  2015-10       Impact factor: 1.276

3.  Outpatient management of oral anticoagulation therapy in patients with nonvalvular atrial fibrillation.

Authors:  Aida Kulo; Nedzad Mulabegović; Jasna Kusturica; Hasija Hadzić; Lejla Burnazović-Ristić; Maida Rakanović-Todić; Amila Mehmedović; Orhan Lepara
Journal:  Bosn J Basic Med Sci       Date:  2009-11       Impact factor: 3.363

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.